Ufuk Eren’s Post

We are pleased to present the EY German Biotech Report 2024, which has been produced in close cooperation with BIO Deutschland e. V.   Our analysis of the year 2023 reveals the strengths and weaknesses of Germany’s biotech industry. Download the full report for a deeper-dive into the status quo of the industry and detailed information about the international standing, the financing cycle, alliances, M&A trends, clinical pipeline as well as the technological convergence of AI and biotechnology: https://lnkd.in/dwrQdV9t   Let's discuss the future of biotech and AI – I welcome your thoughts and questions in the comments below. #EYBiotech #BioDeutschland #Biotechnologie

Ready, Set, Growth! Released this morning at #BIO2024, we unveiled findings from a new assessment of biotech stakeholders about the state of the industry and transformation on the horizon. The big takeaway: outlooks are bright, interest in drug discovery is dominant, and 79% of respondents predict industry growth in the next year. Read our new report for actionable insights on top areas of interest, women's health and anticipated disruptions from policy and technology, and how these factors are fueling biotech. https://lnkd.in/eytfXgM8 #wewillcure

More employees, lower total revenue, and a promising research pipeline: In the current EY Biotech report 2024 you can read about the state of the industry: https://lnkd.in/e2GdPNF3 #EYbiotech #BetterQuestions #BetterAnswers

More employees, lower total revenue, and a promising research pipeline: In the current EY Biotech report 2024 you can read about the state of the industry: https://lnkd.in/epFWTzMF #EYbiotech #BetterQuestions #BetterAnswers

IBioIC25 will be the Industrial Biotechnology Innovation Centre’s 11th Annual Conference. This not-for-profit conference is the industry event of the year for the industrial biotechnology community in Scotland, and one of the pre-eminent events in the global biotech calendar. The conference attracts biotech professionals from industry, research and academia, as well as policy-makers, service providers, and emerging client sectors. The 2025 conference will focus on delivering tangible benefits for attendees, including the cultivation of strategic partnerships, facilitating new connections and collaborations, providing examples of best practice, understanding regulations, and effective communication. Find out more and plan your attendance: https://lnkd.in/emu-zyTd #Innovation #Biotechnology #Collaboration

More employees, lower total revenue, and a promising research pipeline: In the current EY Biotech report 2024 you can read about the state of the industry: https://lnkd.in/ez94ymt9 #EYbiotech #BetterQuestions #BetterAnswers

More employees, lower total revenue, and a promising research pipeline: In the current EY Biotech report 2024 you can read about the state of the industry: https://lnkd.in/eYaWkNYf #EYbiotech #BetterQuestions #BetterAnswers

◾ Do all #biotech companies have the same potential and risk profile? ◾ If you would like to learn more about this topic listen to a panel discussion "Alternative investment models in biotechnology" that will take place during the PHASE - Polish Healthcare Assets Sector Event. ◾ Piotr Garstecki (CEO Scope Fluidics) will participate in this debate as one of the invited guests. *** The PHASE - Polish Healthcare Assets Sector Event is the largest discussion on Polish biotechnology. The Conference is aimed at all those interested in medical biotechnology, including: ▪ Capital market participants ▪ Representatives of public institutions ▪ Entrepreneurs ▪ Scientists The PHASE - Polish Healthcare Assets Sector Event will be held on August 27-29, 2024. 🔥 Join the panel discussion - "Alternative investment models in biotechnology" - August 28,2024/ 14:00 🌍 www - https://lnkd.in/dpj26xHs #PHASE2024 #biotechnology #scopefluidics #deeptech #business #gospodarka #technologie #nauka #innowacje #medycyna #zdrowie

🔬 Poland's Biotechnology Breakthroughs: A New Era in Innovation 🔬 In the latest episode of Poland Weekly's Business Focus, host Sylwia Ziemacka sits down with Marta Winiarska, President of the Board at BioInMed to explore the rapid growth of Poland's biotechnology sector and its rise on the global stage. Key insights from the interview include: 🌍 Poland's Growing Role in Global Biotech: From early biotech R&D to being recognized as a global player, Marta shares how Poland is making waves in this high-tech field. 💼 Attracting Talent and Investment: Learn what makes Poland's biotech sector a hotspot for international investors and top talent, from cutting-edge technologies to a strong education system. 🤝 The Power of Partnerships: Discover how collaborations with global pharmaceutical giants are driving Polish innovations to the next level. 🚀 From Manufacturing to Innovation: Marta highlights Poland's transition from being the "manufacturer of Europe" to becoming a biotech innovator. Tune in to hear about the success stories transforming Poland’s economy and its place in the global biotech industry. #Biotechnology #Innovation #PolandBiotech #PolishEconomy #GlobalInvestment #PolandWeekly #BusinessFocus #BigPharma #MedicalSector #Healthcare

Explore how biotechs can unlock early value in their commercial journey and look ahead to a brighter future at the 2024 Fierce Biotech Summit. Don’t miss our presentation in the Strategy and Dealmaking track at 2:30pm on September 30. #commercialsuccess #biotech #innovation Karla Anderson, Maya K. Desai, PhD, Michele Fuller